argenx (ENXTBR:ARGX) Starts Tender Offer With Board Backing In Pipeline Push

• argenx (ENXTBR:ARGX) has launched a tender offer to acquire Forte Biosciences in a deal backed by Forte's Board of Directors.
• The offer gives Forte shareholders the option to sell their shares directly into argenx's bid under agreed terms.
• The Forte Board's recommendation signals alignment on the transaction and may help smooth the path to completion.

Moves like argenx's push into additional clinical assets are part of a broader search for under-covered growth stories in healthcare, and you can scan a wider set of those opportunities here: screener containing 548 high quality undiscovered gems

argenx sits in the global biotech sector, where investor attention often swings with clinical and deal news rather than steady cash flows. The stock has been volatile yet positive over longer periods, with a return of 34.3% over 1 year and 186.3% over 5 years from a recent share price of €763.2. That track record keeps argenx on the radar for investors watching complex drug development stories.

We've flagged 2 risks for argenx. See which could impact your investment.

How the Forte Biosciences deal fits the argenx growth story

The core argenx Narrative is that Vyvgart is the foundation, and carefully chosen immunology assets extend that into a broader, multi-indication growth story. This Forte move sits squarely in that effort to widen the opportunity set while tackling concentration risk.

"Strategic partnerships and advances in disease targeting are expanding market opportunities and operational efficiencies, supporting long-term growth potential..."

Read the full argenx narrative to see the case behind these numbers

The Forte Biosciences tender offer is a test of that Narrative in practice. argenx is leaning into its specialty in autoimmune disease and adding FB102, a CD122 antibody that targets immune driven conditions such as vitiligo and celiac disease. That lines up with the idea of expanding into adjacent diseases rather than venturing into unrelated areas.

For investors concerned about heavy dependence on Vyvgart, this deal speaks directly to the concentration risk flagged in the Narrative. It adds another late stage program that could eventually help diversify earnings away from a single product focus, similar to how competitors like AstraZeneca and Roche have tried to build broader immunology franchises.

The acquisition does not remove the existing risks around pricing pressure, high R&D spend or future reimbursement, and it introduces the usual execution questions on integration and clinical strategy. Analysts have also highlighted that gross to net pressures and a crowded autoimmune space, with drugs such as UPLIZNA in myasthenia gravis and related markets, still matter for argenx even as the pipeline widens.

Every number here only means something against the Narrative you hold for the company.

To ensure you're always in the loop on how the latest news impacts the investment narrative for argenx, head to the community page for argenx to never miss an update on the top community narratives.

Stay updated on the most important news stories for argenx by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on argenx.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com